Cart
sales@molnova.com
Benzidine orange
CAS No. 3520-72-7
Benzidine orange( Polymo Orange GR | DCC 1802 | DCC-1802 | DCC1802 | Oralith Orange PG )
Catalog No. M27327 CAS No. 3520-72-7
Benzidine orange shows mutagenic and carcinogenic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | In Stock |
|
| 10MG | 63 | In Stock |
|
| 25MG | 103 | In Stock |
|
| 50MG | 150 | In Stock |
|
| 100MG | 223 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 482 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBenzidine orange
-
NoteResearch use only, not for human use.
-
Brief DescriptionBenzidine orange shows mutagenic and carcinogenic activity.
-
DescriptionBenzidine orange shows mutagenic and carcinogenic activity.
-
In Vitro——
-
In Vivo——
-
SynonymsPolymo Orange GR | DCC 1802 | DCC-1802 | DCC1802 | Oralith Orange PG
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3520-72-7
-
Formula Weight623.5
-
Molecular FormulaC32H24Cl2N8O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=NN(C(=O)C1\N=N\c1ccc(cc1Cl)-c1ccc(\N=N\C2C(C)=NN(C2=O)c2ccccc2)c(Cl)c1)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lo Celso C, et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche.
molnova catalog
related products
-
Sincalide ammonium
Sincalide ammonium (Cholecystokinin octapeptide ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography.
-
4-Methylumbelliferon...
A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent.
-
TT-10
TT-10 (TAZ-K), an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity, has potential application in heart disease research, specifically for conditions characterized by loss of cardiomyocytes.
